Guk-Hyun Hwang

OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung.

BCM Europe AG provides investment and financial advisory services. The private company is based in Zug, Switzerland and has subsidiaries in Switzerland. Guk-Hyun Hwang has been the CEO of the Swiss company since 2020.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.